Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study. by Cihoric, Nikola et al.
RESEARCH Open Access
Highly conformal combined radiotherapy
with cisplatin and gemcitabine for
treatment of loco-regionally advanced
cervical cancer – a retrospective study
Nikola Cihoric1* , Alexandros Tsikkinis1, Eugenia Vlaskou Badra1, Markus Glatzer1,3, Urban Novak2, Amina Scherz2,
Mohamed Shelan1, Ivan Soldatovic3, Chittazhathu Kurian Kuruvilla Yojena2, Daniel M. Aebersold1 and Kristina Lössl1
Abstract
Background: Cisplatin and gemcitabine combined with conventional radiation therapy in the treatment of cervical
cancer patients results in a favorable outcome but with excess toxicity. The purpose of this study was to evaluate
the toxicity profile of dual chemotherapy and highly conformal external beam radiotherapy with image guided
adaptive brachytherapy.
Methods: Seventeen patients with cervical carcinoma FIGO stage IB2–IIIB were treated with curative intent between
2011 and 2015. A total dose of 50.4 Gy was prescribed to the elective pelvic nodal volume. Patients with 18FDG-PET/CT
positive lymph nodes (n = 15; 83.3%) received an additional boost to a total dose of 62 Gy. Chemotherapy prescription
goals were: concomitant during 5 weeks of external beam radiotherapy (EBRT) 40 mg/m2 cisplatin and 125 mg/m2
gemcitabine, followed by adjuvant chemotherapy from week 10 (2 cycles 50 mg/m2 cisplatin and 1000 mg/m2 gemcitabine).
EBRT was followed by 3–4 fractions (6 Gy per fraction) of intrauterine image guided adaptive brachytherapy. Toxicities were
graded according to the common terminology criteria for adverse events (CTCAE v 4.0).
Results: One (6%) patient developed acute grade 3 diarrhea. We did not record any other acute or late gastrointestinal or
urogenital toxicity higher that grade 3. Most common acute hematological toxicity was anemia grade 2 recorded in 10 (59%)
patients. There was only one case of grade 3 neutropenia (6%). The number of patients that received the complete
chemotherapy regimen was gradually declining during the course of therapy. From week 2 to 5, gemcitabine was
omitted in 4 (24%),7 (41%), 8 (47%), and 12 (71%) patients respectively, similarly, cisplatin was omitted in 2 (12%),3
(18%),1 (6%) and 7 (41%) patients respectively. Adjuvant chemotherapy was omitted in 8 patients (47%). During a
median follow-up time of 20 months (5 to 63 months) 6 (35%) patients developed disease relapse with 5 (29%) of
them in the form of systemic disease.
Conclusions: In contrast to previous findings cisplatin and gemcitabine in combination with highly conformal radiation
therapy seems to have an acceptable toxicity profile. Further studies are needed to determine the optimal dosage of the
proposed therapy concept.
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Background
The standard therapeutic approach for patients with
loco-regionally advanced cervical cancer is combined
radio-chemotherapy (RCT). Several large prospective
randomized clinical trials have shown that the combin-
ation of radiotherapy with cisplatin based chemotherapy
prolongs the disease-free survival while reducing mortal-
ity. Even though the outcome of RCT is better than that
of radiation alone, the combined regimen is associated
with a higher incidence of side effects while distant disease
control and overall survival remains unsatisfactory [1, 2].
Between 20 and 40% of patients treated with conventional
radiotherapy will relapse loco-regionally, not only outside
of the treatment volume but also within [3].
At the same time, rapid advancements in the radiation
delivery technology and techniques as well as cancer
imaging were achieved. These changes are well mirrored
in a significantly improved therapeutic ratio of intensity
modulated radiotherapy (IMRT) for various tumor
entities, including cervical cancer [4]. The incorporation
of multimodal imaging, especially in patients with cervical
cancer, enhances the detection of nodal and/or systemic
disease while allowing better patient selection and defin-
ition of loco-regional disease [5, 6]. It is now possible to
treat lymph node metastases using dose escalated radio-
therapy without significant toxicity and modern image
guided adaptive brachytherapy (IGABT) results in local
control higher than 90% [7].
Nevertheless and despite of all the advances made pos-
sible, systemic disease recurrence after treatment remains
a problem. The challenge of reducing disease recurrence
is well known and the potential answer to it may indeed
lie in the addition of a further chemotherapy agent to the
current standard of care with single agent cisplatin.
Based on the improved treatment results of doublet
chemotherapy, published by Dueñas-Gonzáles et al. [8],
and excellent toxicity profile achieved with highly con-
formal radiotherapy, we used a combination of cisplatin
and gemcitabine as standard concomitant and adjuvant
chemotherapeutic combination for patients with loco-
regionally advanced cervical cancer in 2011.
The goal of this study was to evaluate early toxicity of
doublet concomitant chemotherapy (cisplatin and gemci-
tabine) followed by two adjuvant cycles, with dose esca-
lated volumetric modulated external beam radiotherapy
followed by intrauterine IGABT.
Methods
Patients
Patients with histologically confirmed cervical cancer, FIGO
stage IBI to IVA, treated with IMRT and concomitant com-
bined chemotherapy with cisplatin and gemcitabine at the
Bern University Hospital Department of Radiation Oncology
were included in this retrospective study according to the
institutional ethical standards.
We evaluated all medical and radiotherapy records, pre-
treatment and follow-up data as well as radiographic images
of 17 patients treated between May 2011 and December
2015. Patient characteristics are summarized in Table 1.
Staging and treatment
All patients underwent a pretreatment staging workup as
defined by institutional standards (medical history, general
physical and gynecological examination under anesthesia,
digital rectal examination, tumor biopsy, comprehensive
laboratory blood analysis, rectoscopy and cystoscopy).
Table 1 Patient Characteristic
No. %
FIGO Stage
IB 3 16.7%
IB1 7 38.9%
IB2 1 5.6%
IIA 1 5.6%
IIB 3 16.7%
IIIA 2 11.1%
IIIB 1 5.6%
Nodal Status
pN1 7 38.9%
cN1 9 50.0%
cN0 2 11.1%
Tumor Size
< 4 cm 3 16.7%
> 4 cm 15 83.3%
Number of metastatic lymph nodes
0 2 11.1%
1 6 33.3%
2 4 22.2%
3 1 5.6%
> 3 5 27.8%
Presence of metastatic para-aortic lymph nodes
No 13 72.2%
Yes 5 27.8%
Tumor hystological type
Squamous cell carcinoma 13 72.2%
Adenocarcinoma 5 27.8%
Tumor grade
G1 0 0.0%
G2 13 72.2%
G3 2 11.1%
Data not available 3 16.7%
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Tumor staging was defined according to the International
Federation of Obstetrics and Gynecology (FIGO) and the
TNM-UICC system (7th edition). Further staging and
radiotherapy as well as surgical treatment details are de-
scribed in detail in our previously published work [9, 10].
Radiotherapy
Contouring: Image sets acquired by CT, diagnostic 18FDG-
PET/CT and MRI were imported into the Eclipse Planning
System (Varian Medical System, Palo Alto, CA). The gross
tumor volume of the cervix (GTVc) was defined as the vis-
ible macroscopic tumor based on all of the available clinical
and imaging data. Clinical target volume for primary tumor
area (CTVc) encompassed GTVc, uterus, parametria and
the upper third of the vagina. In cases of vaginal involve-
ment, CTVc was expanded 2 cm into the vagina caudally of
the tumor. The planning target volume of the primary
tumor (PTVc) was created using anisotropic expansion,
taking cervical and surrounding structure movements into
consideration. The PTVc was expanded to 15 mm in the
antero-dorsal direction and 10 mm in the lateral direction.
PTVc was manually corrected when needed. In the dorsal
direction PTVc margin extended maximally to the poster-
ior rectal wall and maximally 1.5 cm anteriorly into the
bladder [11].
Dose Prescription: In the first phase PTVc was irradi-
ated with a total dose of 50.4 Gy. After 45 Gy a control
MRI was performed to evaluate tumor response and
measure tumor size. In cases where the remaining tumor
was larger than 4 cm in diameter, an additional EBRT
boost of 9 Gy was administered to the PTVc. Otherwise,
for tumors smaller than 4 cm in diameter, the PTVc was
irradiated with an EBRT boost of 5.4 Gy. The single dose
used was always 1.8 Gy.
Dose Constraints: Dose constraints for organs at risk
were standardized as follows: 60% of rectal volume should
receive no more than 50 Gy, 35% of bowel volume should
receive no more than 35Gy, 50% of bladder volume
should receive no more than 50 Gy and 10% of the fem-
oral heads volume should receive no more than 50 Gy.
Brachytherapy: EBRT was followed by a HDR boost to
the primary tumor. We used a microSelectron® HDRB Unit
and a Vienna Ring CT-MRI Applicator Set. MRI images
were evaluated together with our radiology department to
define the high and intermediate risk areas. Afterwards, we
reconstructed the high risk and intermediate risk areas
detected in the MRI images on our planning CT images
[12, 13]. Brachytherapy consisted of a total dose of 18 Gy
delivered in 4 weekly fractions, with a single dose of 6 Gy.
Chemotherapy
All patients were scheduled to receive cisplatin 40 mg/m2
by intravenous infusion over 60 min followed by gemcita-
bine 125 mg/m2 administered by intravenous infusion
over 30 min once a week for 6 weeks, combined with radi-
ation treatment on days 1–5 over 6 weeks respectively.
Immediately after completion of the chemo-radiotherapy
schedule, patients underwent brachytherapy (BCT) in
week 7, followed by two weeks of rest. Thereafter patients
underwent two consecutive 21-day cycles of adjuvant
chemotherapy with cisplatin 50 mg/m2 on day 1 and gem-
citabine 1000 mg/m2 on days 1 and 8. The treatment
schema was based on rules defined by Dueñas-González
et al. [8].
Dose reduction rules
According to the internal standards of the University
Hospital of Bern, multiple variables were controlled and
were required to be met to fulfill the necessary safety
requirements prior to each chemotherapy cycle: ECOG
0–2, thrombocytes >100 G/l, leucocytes >3 G/L or neu-
trophils >1.0 G/l, neurotoxicity less than grade 3 accord-
ing to CTCAE v4 and calculated creatinine clearance of
at least 60 ml/min (by Cockcroft-Gault). These factors
were evaluated weekly by the responsible oncologists.
In cases of hematological toxicity, or reduced general
condition, gemcitabine was reduced or omitted, in cases
of neurotoxicity, or renal insufficiency cisplatin was
reduced or omitted. Erythrocyte transfusion limit was
Hb ≤ 80 g/l. In cases of fever and infection, chemother-
apy dose was delayed.
Supportive therapy for prevention of nausea, kidney
damage, hematologic toxicity
Concomitant treatment for the prevention of nausea were
aprepitant (125 mg on the first day of chemotherapy and
80 mg on the second and third day), methylprednisone
(125 mg on the first day) and dexamethasone (4 mg from
the second to the fourth day).
In order to prevent kidney damage, hydration treat-
ment was provided by intravenous infusion of 1000 ml
fluid before and after cisplatin application (0.9% NaCl
before and Glucosaline 2:1 after cisplatin +10 mm KCl and
8 mm MgCl2). Sodium Chloride and Glucose Solution for
Infusion 0.18% and 4%.
Erythrocyte transfusions were given for symptomatic
anemia or hemoglobin levels ≤80 g/l. Platelet transfu-
sions were given for Tc < 20 G/l with bleeding or fever,
otherwise if <10G/l. Filgrastim was used to prevent
severe neutropenia.
Statistical methodology: Results are presented as count
(percent) or median (minimum-maximum). The Kaplan-
Meier curve was used for disease-free survival (DFS)
analysis. DFS was measured from the first day of therapy
to the first, clinical or radiological or metabolic sign
of disease.
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Results
Treatment related toxicities
There were no significant pauses or omissions of radiother-
apy. The number of omitted chemotherapy applications
during the concomitant part is presented in Fig. 1. Adjuvant
combined gemcitabine / cisplatin chemotherapy was given
in 10 (58.8%) and 9 (52.9%) patients in the first and second
adjuvant cycle respectively.
Treatment related toxicities were recorded in the major-
ity of patients (n = 15; 88.2%), however we did not record
any kind of life threatening toxicities (≥grade 4 CTCAE
v4.0) and there were no treatment related deaths recorded.
Acute toxicities
Diarrhea was recorded in 9 (52.9%) patients, of those 4
(23.5%) were grade 1, 4 (23.5%) were grade 2 and 1 (5.9%)
was grade 3. Nausea was noted in 5 (29.4%) patients, of
those grade 1 in 2 (11.8%), grade 2 in 1 (5.9%) and grade 3
in 2 (11.8%) patients. Acute cystitis was noted in 4 (23.5%)
patients, of those 3 (17.6%) grade 1 and 1 (5.9%) grade 2.
Vaginitis emerged in 4 (23.5%) patients during treatment,
of those 3 (17.6%) patients had grade 1 and 1 (5.9%) grade
2. No other gastrointestinal or genitourinary toxicities
were reported.
Other therapy related acute toxicities were recorded as
follows: 1 patient (5.9%) developed a lymphocele with con-
sequent ureteral obstruction that required a nephrostomy
and surgical intervention afterwards (as a direct conse-
quence of prior lymphadenectomy). Two (11.8%) patients
developed polyneuropathy grade 2. Furthermore, one
(5.9%) patient developed intraabdominal fat tissue necro-
sis that was treated conservatively and one (5.9%) patient
developed low back and pelvic pain grade 2. A commonly
described adverse event was fatigue (n = 8, 47.1%), grade 2
in seven (41%) patients and grade 3 in 1 (6%) patient.
Acute hematological toxicities during concomitant radio-
chemotherapy are presented in Fig. 2 in the form of cumu-
lative incidence.
Chronic toxicities
Chronic gastrointestinal or urogenital toxicity was reported
or diagnosed in 10 (58.8%) patients. Five (29.4%) reported
upper gastrointestinal toxicities grade 1, 4(23.5%) reported
cystitis grade 1, and one patient (5.9%) grade 2. Two (11.8%)
patients reported vaginal dryness grade 1, one (5.9%) short-
ening of vagina grade 1, and two (11.8%) patients reported
grade 3 toxicities in the form of a vaginal stenosis.
Survival
Within a median follow-up of 25 months (range 5 to
62 months) 7 (41.2%) patients developed disease recurrence.
One (5.9%) patient developed an isolated local relapse and
one (5.9%) local relapse with simultaneous systemic meta-
static disease. Two (11.8%) patients developed regional
nodal relapse with one of them also developing systemic
metastases. In total 6 (35.3%) patients developed systemic
metastases. One of them died one year after diagnosis of
systemic disease and two of them died years after diagnosis
of systemic disease. Three patients with metastatic disease
were alive at the time of our last follow up.
One (5.9%) patient developed lung metastases (detected
by 18FDG-PET/CT) six months after initial therapy, treated
with wedge resection. The patient was disease free at the
point of our last follow-up visit at 62 months after initial
therapy and 56 months after resection of the metastasis.
One (5.9%) patient developed a solitary liver metastasis
13 months after initial treatment. She was surgically treated.
After 4 months, this patient showed a new FDG-active
lesion within the former tumor bed in the liver for which
she received stereotactic body irradiation. The patient was
Fig. 1 Number of omitted chemotherapies expressed in absolute numbers
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alive and in good health, without any signs of tumor during
our last follow up 60 months after initial treatment and
36 months after treatment for metastatic disease.
Median disease free survival was 57 months (range:
32.9–81.3 months). Kaplan-Meier curve for disease free
survival is shown in Fig. 3.
Discussion
Radiotherapy alone in the treatment of loco-regionally
advanced cervical cancer has unsatisfactory results. With
the aim of enhancing treatment outcome several trials
were designed and conducted by the end of the last cen-
tury. The combined results of those pivotal trials were
Fig. 2 Hematological toxicities during concomitant radio-chemotherapy
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evaluated in a meta-analysis conducted on individual pa-
tient data by Vale C. et al. The addition of chemotherapy
reduced both, local and distant recurrence and resulted
in a 6% improvement in the 5-year survival compared
with radiotherapy alone [14].
A combination of two chemotherapy agents may have an
additive effect. Besides cisplatin, gemcitabine has shown a
radio-sensitizing effect in vitro as well as in vivo [15–18].
Burnett A.F. described a 41% overall response rate with an
acceptable toxicity profile [19]. Dueñas- González et al. (2001)
explored the neo-adjuvant application of cisplatin / gemcita-
bine chemotherapy. The most common hematological tox-
icity was granulocytopenia grade 3 and 4 in 13.8% and 3.4%
of patients respectively [20]. Further analysis showed that the
neo-adjuvant approach is at least as effective as standard con-
current cisplatin based radio-chemotherapy [21].
Zarbá JJ et al. conducted a phase I/II study of weekly
cisplatin and gemcitabine on 36 patients and found that
the maximum-tolerated dose for Gemcitabine was
150 mg/m2 [22]. Further Umanzor J et al. conducted a
phase II trial on 23 patients resulting in an acceptable
toxicity profile with only one case of grade 3 neutro-
penia, no grade 4 hematological toxicities and no un-
usual late radiation toxicities [23].
Those early data were supported by a pivotal trial
conducted by Dueñas-González. Investigators compared
concurrent gemcitabine plus cisplatin and radiation
followed by adjuvant gemcitabine and cisplatin with con-
current cisplatin and radiation in patients with stages
IIB to IVA cervical cancer. Treatment resulted in an im-
proved progression free survival (PFS) at 3 years (74.4%
vs 65.0% p = 0.029), improved overall PFS (log-rank
p = 0.0227; hazard ratio [HR], 0.68; 95% CI, 0.49–
0.95) and overall survival (OS) (log-rank p = 0.0224;
HR, 0.68; 95% CI, 0.49–0.95) and distant failure rate
(8.1% vs. 16.4%, p = 0.005). This success was accom-
panied by higher grade 3 and 4 toxicities in the ex-
perimental arm (86.5% vs 46.3%; p < 0.001) [8].
Compared with previous trials our study has several
distinct characteristics regarding methodology and pa-
tients. First of all, our patients were treated with highly
conformal radiotherapy while previous studies utilized
conventional EBRT. This is the possible reason for the
lower incidence of grade 3 hematological toxicities. It
has been shown that IMTR is better compared to two-
dimensional (2D) and three-dimensional (3D) tech-
niques, in terms of both bone marrow sparing and lower
incidence of toxicity [24, 25].
Fig. 3 Kaplan-Meyer Curve for Disease Free Survival
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Our treatment results are comparable with those pub-
lished in literature. Loco-regional control is better than in
previous trials that have used the cisplatin-gemcitabine com-
bination. This may be attributed to the utilization of intra-
uterine adaptive image guided brachytherapy, rather than to
the addition of chemotherapy. Local failure was an issue in
the Dueñas-González trial although the local failure rate did
not differ significantly in the two arms of the study (11.2%
vs. 16.4%, p= 0.097) [8]. Still, disease control is problematic
as 40% of patients developed systemic metastases.
Modern RT technique results in excellent local control
rates. The three year local control rate exceeds 95% irre-
spective of tumor size [26] and reaches almost 100% if the
EQD2 dose to the “high risk tumor volume” exceeds 87 Gy
[7]. These facts point to the conclusion that combining
chemotherapy during radiation does not produce a signifi-
cant effect. However, even in the absence of visible local
disease at the time of RCT, local lymph nodes may still har-
bor microscopic disease and macroscopic disease may also
be present and remained undetected by radiological investi-
gations such as computed tomography or MRI [27, 28]. It
is possible that the administration of combined chemother-
apy during EBRT can lead to the successful eradication of
nodal disease.
Limitations: a major limitation of our study is its retro-
spective nature, and the small number of patients included
in the study. Furthermore, the dose reduction or even omis-
sion of chemotherapy was not done in strict accordance to
internal rules in all patients. More than 70% of all patients
did not receive the prescribed chemotherapy. In addition, it
was not feasible to retrieve all data on the concomitant
chemotherapy, especially regarding the application of gran-
ulocyte colony-stimulating factor. As a consequence of the
previously mentioned limitations we cannot draw a defini-
tive conclusion about the safety of the proposed concept.
Despite these limitations, we believe that this study pro-
vides a unique insight on new possibilities for the treat-
ment of patients with loco-regionally advanced cervical
cancer. The presented data may serve as a starting point
for sample size calculation for future prospective studies.
Conclusions
The proposed treatment regimen seems to be promising
in terms of lower toxicity than previously recorded in
other studies. Further prospective studies with a higher
number of patients are warranted and are necessary for
the definitive confirmation of the safety and efficacy of
the proposed concept.
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